


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	Not Yet Assigned 10/650,591
				Filing Date	August 27, 2003
				First Named Inventor	Noubar B. Afeyan
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	COTH-P02-001


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
[Signature]	AA	2002/0019039-A1	02-14-2002	Davis et al.	
	AB	4,671,958	06-09-1987	Rodwell et al.	
	AC	5,935,823	08-10-1999	Fowlkes et al.	
	AD	6,287,561	09-11-2001	Crea, R.	
	AE	6,383,775-B1	05-07-2002	Duff et al.	
	AF	6,399,355-B1	06-04-2002	Kwong et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	-WO-00/64485-A2	11-02-2000	Genencor-International, Inc. et al.		
	BB	-WO 90/02338-A1	03-08-1990	The General Hospital Corporation		
	BC	-WO 01/42432-A2	06-14-2001	Medical Research Council		
	BD	-WO 98/16633-A1	04-23-1998	Novo Nordisk A/S		
	BE	-WO 02/055108-A1	07-18-2002	Centre National de la Recherche Scientifique et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Signature]	CA	Bayer, E.A. et al. Affinity Cleavage and Targeted Catalysis of Proteins Using the Avidin-Biotin System. Biochemistry 29, 11274-79 (1990).	
	CB	Bond, R. et al. Silicon Biotechnology: New Opportunities for Carbohydrate Science. Aust. J. Chem. 56, 7-11 (2003)	
	CC	Bradbury, R.J. Protein Based Assembly of Nanoscale Parts. (May 1, 2003) Retrieved from http://www.aeiveos.com/~bradbury/Papers/PBAoNP.html on 8/25/03	
	CD	Hosseini, M.W. Molecular Tectonics: From Simple Molecules to Complex Molecular Networks. Universite Louis Pasteur, Strasbourg, France	
	CE	Alvarez, S. Engineering Protein Molecules for the Ordered Structuring of Silica. National Nanofabrication Users Network, pp. 82-3.	
	CF	Davis, B.G. et al. Controlled Site-Selective Glycosylation of Proteins by a Combined Site-Directed Mutagenesis and Chemical Modification Approach. J. Org. Chem. 63, 9614-15 (1998)	
	CG	Davis, B.G. et al. Selective Protein Degradation by Ligand-Targeted Enzymes: Towards the Creation of Catalytic Antagonists. ChemBioChem 4, 531-40 (2003)	
	CH	Freitas, Jr., R.A. Mechanoenzymes: A non-SPM-based approach to molecular	

Examiner Signature	[Signature]	Date Considered	9/4/06
--------------------	-------------	-----------------	--------



PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/AB/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	Not Yet Assigned		
		Filing Date	August 27, 2003		
		First Named Inventor	Noubar B. Afeyan		
		Art Unit	N/A		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	COTH-P02-001

U		mechanoassembly (February 21, 2000) Retrieved from http://www.aeiveos.com/~bradbury/Authors/Engineering/Freitas-RA/MAnSPMBAIMM.html on 8/25/03	
	CI	Sumerel, et al. Biotechnology Provides a New Route to Semiconductors. 2003	
	CJ	MacLennan, Bruce. Molecular Combinatory Computing for Nanostructure Synthesis and Control. Department of Computer Science, University of Tennessee	
	CK	Maoz, R. et al. Self-Assembly and Nanofabrication: Is a Happy Marriage Possible? Department of Materials and Interfaces, The Weizmann Institute of Science, Rehovot, Israel	
	CL	Quake, S.R. et al. From Micro- to Nanofabrication with Soft Materials. Science 290, 1536-40 (November 24, 2000)	
	CM	Stupp, S.I. Self Assembly of Nanostructures and Functional Materials. Dept. of Materials Science and Engineering, Dept. of Chemistry, Feinberg Medical School, Northwestern University	
	CN	Whaley, S.R. et al. Selection of peptides with semiconductor binding specificity for directed nanocrystal assembly. Nature 405, 665-68 (June 8, 2000)	
	CO	Zhou, Huan-Xiang. Quantitative Account of the Enhanced Affinity of Two Linked scFvs Specific for Different Epitopes on the Same Antigen. J. Mol. Biol. 329, 1-8 (2003)	
	CP	Lim et al. BCR/ABL inhibition by an escort/phosphatase fusion protein. PNAS October 24, 2000 97(22): 12233-12238	
	CQ	Runge et al. Mol Biol Med Hybrid molecules: insights into plasminogen activator function. 1991 Apr 8(2):245-55	
	CR	Frankel et al. Diphtheria fusion protein therapy of chemoresistant malignancies. Curr Cancer Drug Targets 2(1), 19-36 (2002)	
U	CS	Springer et al. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT). Anticancer-Drug-Des. 11(8), 625-36 (1996)	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	4/4/03
-----------------------	--	--------------------	--------

91


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 31, 2005 (Use several sheets if necessary)	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">ATTORNEY DOCKET NO.</td> <td style="width: 70%;">APPLICATION NO. 10/650,591</td> </tr> <tr> <td colspan="2">FIRST NAMED APPLICANT Afeyan, Noubar B., <i>et al.</i></td> </tr> <tr> <td>FILING DATE August 27, 2003</td> <td> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">CONFIRMATION NO. 7918</td> <td style="width: 40%;">GROUP 1652</td> </tr> </table> </td> </tr> </table>	ATTORNEY DOCKET NO.	APPLICATION NO. 10/650,591	FIRST NAMED APPLICANT Afeyan, Noubar B., <i>et al.</i>		FILING DATE August 27, 2003	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">CONFIRMATION NO. 7918</td> <td style="width: 40%;">GROUP 1652</td> </tr> </table>	CONFIRMATION NO. 7918	GROUP 1652
ATTORNEY DOCKET NO.	APPLICATION NO. 10/650,591								
FIRST NAMED APPLICANT Afeyan, Noubar B., <i>et al.</i>									
FILING DATE August 27, 2003	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 60%;">CONFIRMATION NO. 7918</td> <td style="width: 40%;">GROUP 1652</td> </tr> </table>	CONFIRMATION NO. 7918	GROUP 1652						
CONFIRMATION NO. 7918	GROUP 1652								

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER	MM-DD-YYYY ISSUE DATE / PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
J	AA	4,975,278	12-04-1990	Bristol-Myers Company
J	AB	5,258,498	11-02-1993	Huston <i>et al.</i>
J	AC	5,961,973	10-05-1999	Crea
J	AD	5,811,265	09-22-1998	Quertermous <i>et al.</i>

FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	MM-DD-YYYY PUBLICATION DATE	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
J	AL	WO 00/64485 A2	11-02-2000	Genencor International, Inc.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
J	AR	Holvoet, Paul, <i>et al.</i> , "Characterization of a Chimeric Plasminogen Activator Consisting of a Single-chain Fv Fragment Derived from a Fibrin Fragment D-Dimer-specific Antibody and a Truncated Single-chain Urokinase," <i>J. Biological Chemistry</i> , 266(29): 19717-19724 (1991).
J	AS	Collen, Desire and Lijnen, H. Roger, "New thrombolytic agents and strategies," <i>Baillière's Clinical Haematology</i> , 8(2): 425-435 (1995).

EXAMINER 	DATE CONSIDERED 9/4/06
--------------	---------------------------



Substitute for form 1449A/B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/650591
				Filing Date	August 27, 2003
				First Named Inventor	Noubar B. Afeyan
				Art Unit	1652
				Examiner Name	Saidha, Tekchand
Sheet	1	of	1	Attorney Docket Number	COTH-P02-001

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AG	US-4,975,278	12-04-1990	Senter et al.	
	AH	US-5,258,498	11-02-1993	Huston et al.	
	AI	US-5,811,265	09-22-1998	Quertermous et al.	
	AJ	US-5,961,973	10-05-1999	Crea	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BF	WO 00/64485-A2	11-02-2000	Genencor-International, Inc. et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CT	COLLEN, D., et al., "New thrombolytic agents and strategies," Bailliere's Clinical Haematology, 8(2):425-435 (1995).	
	CU	HOLVOET, P., et al., "Characterization of a Chimeric Plasminogen Activator Consisting of a Single-chain Fv Fragment Derived from a Fibrin Fragment D-Dimer-specific Antibody and a Truncated Single-chain Urokinase," The Journal of Biological Chemistry, 266(29):19717-19724 (1991).	
	CV	WAGNER, R., Copy of Untimely Filed Protest under 37 C.F.R. § 1.291.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	4/4/03
--------------------	--	-----------------	--------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	COTH-P02-001
-------	---	----	---	------------------------	--------------

Complete If Known

Application Number	10/650591
Filing Date	August 27, 2003
First Named Inventor	Noubar B. Afeyan
Art Unit	1652
Examiner Name	M. Y. Meah

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AK*	US-6,660,492-B1	12-09-2003	Bode et al.	
	AL*	US-20030104520-A1	06-05-2003	Ellington et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BG	WO-03/022858	03-20-2003	NASCACELL GMBH		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	4/4/06
-----------------------	--	--------------------	--------



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

Sheet	1	of	1	Attorney Docket Number	COTH-P02-001
-------	---	----	---	------------------------	--------------

Complete If Known

Application Number	10/650591
Filing Date	August 27, 2003
First Named Inventor	Noubar B. Afeyan
Art Unit	1652
Examiner Name	M. Y. Meah

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
U	AM	US 2004-081647	04-29-2004	Noubar et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
U	BH	WO 97/20038	06-05-1997	The Regents of the University of California		
U	BI	WO 02/097042	12-05-2002	The Trustees of the University of Pennsylvania		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
U	CW	OYAKE et al., "Targeted substrate degradation by an engineered double RING ubiquitin ligase," Biochem Biophys Res Commun. 295:370-375, (2002).	
	CX	NYARUBUCHA et al., "Identification and Expression of the cDNA-encoding Human Mesotrypsin(ogen), an Isoform of Trypsin with Inhibitor Resistance," Journal of Biological Chemistry, 272(16):10573-10578, (1997).	
	CY	SMITH et al., "A detailed study of the substrate specificity of a chimeric restriction enzyme," Nucleic Acids Res. 27(2):674-681, (1999).	
U	CZ	SZMOLA et al., "Human Mesotrypsin Is a Unique Digestive Protease Specialized for the Degradation of Trypsin Inhibitors," Journal of Biological Chemistry, 278(49):48580-48589, (2003).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	4/4/06
--------------------	--	-----------------	--------